Medtronic Receives FDA Clearance of TrailBlazer Angled Peripheral Support Catheter
September 28 2016 - 9:00AM
TrailBlazer Angled
Support Catheter Broadens Medtronic's Leading Peripheral Options
Adding Full Spectrum of Angled Resources to Meet Provider
Needs
DUBLIN - September 28, 2016 -
Medtronic plc (NYSE: MDT) today announced that the U.S. Food and
Drug Administration (FDA) has cleared the TrailBlazer(TM) angled
support catheter for use in the peripheral vascular system. Support
catheters such as the Trailblazer are often used in endovascular
procedures treating complex peripheral artery disease (PAD).
FDA clearance was received on September 23, 2016.
The new TrailBlazer angled support catheter is
designed to support a guide wire during access to the peripheral
arteries, and to enable delivery of solutions and diagnostic
agents. The catheter features a braided stainless steel shaft for
robust pushability and a 25 and 30 degree angled tapered tip to
access and cross complex lesions. To enhance physician visibility,
each of the .014", .018" and .035" guidewire compatible devices is
designed with three radiopaque marker bands and a radiopaque shaft.
Additionally, both the .014" and .018" TrailBlazer angled support
catheter can fit coaxially through the .035" support catheter for
increased reach and pushability.
"Medtronic is committed to providing physicians
with meaningful innovations and therapy choices to enhance their
peripheral treatment algorithm," said Mark Pacyna, vice president
and general manager of the Peripheral business, which is part of
the Aortic & Peripheral Vascular division at Medtronic.
"Working with physicians, we have extended the Medtronic
TrailBlazer support catheter portfolio to offer a broad suite of
angled options for treatment of complex lesions both above and
below the knee."
In collaboration with leading clinicians,
researchers, and scientists worldwide, Medtronic offers the
broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and
cardiac arrhythmias. The company strives to offer products and
services that deliver clinical and economic value to healthcare
consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Krystin Hayward
Public Relations
+1-508-298-8246
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024